<DOC>
	<DOCNO>NCT00827983</DOCNO>
	<brief_summary>Prospective , open , randomise , parallel , multicentre , two arm trial compare new form luteal support ( S.C. ) approve comparator ( vaginal gel ) .</brief_summary>
	<brief_title>Subcutaneous Progesterone Versus Vaginal Progesterone Gel Luteal Phase Support Patients Undergoing In-Vitro Fertilization ( IVF )</brief_title>
	<detailed_description />
	<mesh_term>Progesterone</mesh_term>
	<criteria>Age 18 42 ( upon start COH ) ; BMI &lt; 30 kg/m2 ; &lt; 3 prior ART cycle ( IVF , ICSI relate procedure ) ; Baseline ( day 23 cycling ) FSH &lt; 15 IU/L E2 &lt; 80 pg/mL ; Normal uterine cavity per recent hysterosalpingogram , sonohysterogram hysteroscopic exam ( i.e . polyp protrude submucosal fibroid ) ; At least 3 retrieved oocyte ; Patient give write informed consent . Intramural uterine fibroid distort uterine cavity polyp &gt; 1 cm ; Stage III IV endometriosis ( endometriomas ) ; Hydrosalpinx ; History past poor response COH result cancel ART ; Use thawed/donated oocyte ; Use thawed/donated embryo ; Patients affect pathology associate contraindication pregnant ; Hypersensitivity study medication ; Uncontrolled adrenal thyroid dysfunction ; Undiagnosed vaginal bleeding ; History arterial disease ; Patients hepatic impairment ; Neoplasias ( current ) history neoplasia may responsive progesterone ; High grade cervical dysplasia ; Active thrombophlebitis thromboembolic disorder , history hormoneassociated thrombophlebitis thromboembolic disorder ; History recurrent pregnancy loss define 3 spontaneous miscarriage wherein pregnancy develop minimum gestational sac TVUS ; Participation concurrent clinical trial another trial within past 2 month ; Use concomitant medication might interfere study evaluation ; Preimplantation genetic diagnosis/screening .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Luteal Phase Support IVF patient</keyword>
</DOC>